Unknown

Dataset Information

0

Kidney Histopathology of Patients with Hepatitis C Infection and Diabetes Mellitus before and after Availability of Direct-Acting Antiviral Therapy

ABSTRACT:

SUBMITTER: Kung V 

PROVIDER: S-EPMC11018331 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease.
| S-EPMC7094798 | biostudies-literature
Unknown Low Complement C4 Predicts Improvement of Kidney Function After Direct-Acting Antiviral Therapy for Hepatitis C Virus.
| S-EPMC7395066 | biostudies-literature
Unknown Changes in Hepatic Steatosis Before and After Direct-Acting Antiviral Treatment in People With HIV and Hepatitis C Coinfection.
| S-EPMC11793071 | biostudies-literature
Unknown Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C.
| S-EPMC6563580 | biostudies-literature
Unknown Diabetes Mellitus Increases the Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Therapy: Systematic Review and Meta-Analysis.
| S-EPMC8558240 | biostudies-literature
Unknown Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.
| S-EPMC7244104 | biostudies-literature
Unknown Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era.
| S-EPMC8384709 | biostudies-literature
Unknown Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
| S-EPMC4834854 | biostudies-literature
Unknown Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis.
| S-EPMC10656532 | biostudies-literature
Unknown Barriers to hepatitis C direct-acting antiviral therapy among HIV/hepatitis C virus-coinfected persons.
| S-EPMC7904967 | biostudies-literature